CN105001223A - Entecavir crystalline compound and capsule preparation thereof - Google Patents
Entecavir crystalline compound and capsule preparation thereof Download PDFInfo
- Publication number
- CN105001223A CN105001223A CN201510372885.2A CN201510372885A CN105001223A CN 105001223 A CN105001223 A CN 105001223A CN 201510372885 A CN201510372885 A CN 201510372885A CN 105001223 A CN105001223 A CN 105001223A
- Authority
- CN
- China
- Prior art keywords
- entecavir
- capsule
- crystalline compounds
- starch
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960000980 entecavir Drugs 0.000 title claims abstract description 127
- 239000002775 capsule Substances 0.000 title claims abstract description 79
- 150000001875 compounds Chemical class 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 title claims abstract 22
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 25
- 239000000314 lubricant Substances 0.000 claims abstract description 11
- 229910017488 Cu K Inorganic materials 0.000 claims abstract description 7
- 229910017541 Cu-K Inorganic materials 0.000 claims abstract description 7
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 7
- 239000002904 solvent Substances 0.000 claims abstract description 7
- 239000011230 binding agent Substances 0.000 claims abstract description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 20
- 239000007864 aqueous solution Substances 0.000 claims description 18
- 239000013078 crystal Substances 0.000 claims description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 15
- 229920002472 Starch Polymers 0.000 claims description 15
- 239000008107 starch Substances 0.000 claims description 15
- 235000019698 starch Nutrition 0.000 claims description 15
- 229940032147 starch Drugs 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 13
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 13
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 12
- 229930195725 Mannitol Natural products 0.000 claims description 12
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000000594 mannitol Substances 0.000 claims description 12
- 235000010355 mannitol Nutrition 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 11
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 9
- 239000011122 softwood Substances 0.000 claims description 9
- 235000020985 whole grains Nutrition 0.000 claims description 9
- 229920001353 Dextrin Polymers 0.000 claims description 8
- 239000004375 Dextrin Substances 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 8
- 235000019425 dextrin Nutrition 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 229920000881 Modified starch Polymers 0.000 claims description 7
- -1 Natvosol Polymers 0.000 claims description 7
- HLLPKVARTYKIJB-MCQPFKOBSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@H]1[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O1 HLLPKVARTYKIJB-MCQPFKOBSA-N 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000012046 mixed solvent Substances 0.000 claims description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 6
- 235000012239 silicon dioxide Nutrition 0.000 claims description 6
- 229960001866 silicon dioxide Drugs 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 229960004132 diethyl ether Drugs 0.000 claims description 5
- 239000012065 filter cake Substances 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 238000001291 vacuum drying Methods 0.000 claims description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical class [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 239000000395 magnesium oxide Substances 0.000 claims description 4
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 4
- 229920000523 polyvinylpolypyrrolidone Chemical class 0.000 claims description 4
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 4
- 239000001253 polyvinylpolypyrrolidone Chemical class 0.000 claims description 4
- 239000002002 slurry Substances 0.000 claims description 4
- QIZPVNNYFKFJAD-UHFFFAOYSA-N 1-chloro-2-prop-1-ynylbenzene Chemical compound CC#CC1=CC=CC=C1Cl QIZPVNNYFKFJAD-UHFFFAOYSA-N 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 3
- 238000003825 pressing Methods 0.000 claims description 3
- 229940035023 sucrose monostearate Drugs 0.000 claims description 3
- 229920002785 Croscarmellose sodium Chemical class 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229940024546 aluminum hydroxide gel Drugs 0.000 claims description 2
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 235000001727 glucose Nutrition 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical class OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 229960001375 lactose Drugs 0.000 claims description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 235000019198 oils Nutrition 0.000 claims description 2
- 239000012188 paraffin wax Substances 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 2
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 2
- 239000008109 sodium starch glycolate Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000002075 main ingredient Substances 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 238000001727 in vivo Methods 0.000 abstract description 4
- 239000000945 filler Substances 0.000 abstract description 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 2
- 238000012404 In vitro experiment Methods 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
- QDGZDCVAUDNJFG-FXQIFTODSA-N entecavir (anhydrous) Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)C1=C QDGZDCVAUDNJFG-FXQIFTODSA-N 0.000 description 105
- 239000003814 drug Substances 0.000 description 17
- 208000002672 hepatitis B Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 10
- 241000700721 Hepatitis B virus Species 0.000 description 9
- 229960003943 hypromellose Drugs 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 206010013786 Dry skin Diseases 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 239000008187 granular material Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 208000019425 cirrhosis of liver Diseases 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108700024845 Hepatitis B virus P Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 229960003194 meglumine Drugs 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 235000010603 pastilles Nutrition 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- ZTWBIZVVFNIRSF-HAFWLYHUSA-N [(1s,3s,5s)-3-(2-amino-6-oxo-3h-purin-9-yl)-5-hydroxy-2-methylidenecyclopentyl] [hydroxy(phosphonooxy)phosphoryl] hydrogen phosphate Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](OP(O)(=O)OP(O)(=O)OP(O)(O)=O)C1=C ZTWBIZVVFNIRSF-HAFWLYHUSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 229940002637 baraclude Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000005955 light diet Nutrition 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000009512 pharmaceutical packaging Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229940048102 triphosphoric acid Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
An entecavir crystalline compound and a capsule preparation containing the entecavir crystalline compound are provided. The X-ray powder diffraction of the crystalline compound measured by Cu-K alpha1 is shown as Figure 1. The capsule preparation containing the entecavir crystalline compound comprises the components of an entecavir crystalline compound, a solubilizer, a filler, a disintegrating agent, a lubricant and a binder. The entecavir capsule provided by the invention uses pharmaceutical excipients almost with no side effects on the human body, and the in vivo and in vitro experiments show that the entecavir capsule can be released in a short time to achieve therapeutic plasma concentration and maintain therapeutic plasma concentration for a long time.
Description
Technical field
The present invention relates to a kind of oral nucleoside medicine Entecavir crystalline compounds and capsule preparations thereof of Anti-HBV activity.
Background technology
Chronic viral hepatitis B (Chronic Viral Hepatitis B, CH-B) is a kind of common disease of serious harm human health, and the control of chronic viral hepatitis B is a global public health problem, has caused the concern of countries in the world.The whole world about has several hundred million people to infect hepatitis B virus, and wherein chronic hepatitis B carriers about has 400,000,000 people.In infected patient, about have 15% ~ 40% will develop into liver cirrhosis, liver declines or liver cancer.In hepatitis B virus carriers, the people of 50% ~ 75% has the chronic viral hepatitis B of reactivity virus replication, estimates that the incidence being liver cirrhosis from chronic viral hepatitis B progress in 5 years is 2% ~ 20%; Be 20% ~ 23% from Compensated cirrhosis to Liver failure; Be 6% ~ 15% from compensatory liver cirrhosis to liver cancer.The whole world has every year dies from primary hepatocarcinoma more than 500,000 people, and wherein nearly the primary hepatocarcinoma of 80% caused by chronic viral hepatitis B, hepatitis B has become the global the tenth-largest cause of death.The whole world several hundred million Chronic Hepatitis B has 75% to live in the Asian-Pacific area, and China is the district occurred frequently of viral hepatitis, and the incidence rate in an average annual is 120 ~ 1,400,000, is wherein outstanding with hepatitis B (HB) especially.China hepatitis B virus (HBV) infection rate is up to 57.63%, and namely the whole nation has at least 600,000,000 people to infect HBV.HBsAg positive rate 9.75%, about has 1.2 hundred million people, accounts for 1/3 of the whole world; Wherein about 1/4 will develop into chronic hepatopathy, some patients can develop into liver cirrhosis, even develops into liver cancer.There is existing disease Chronic Hepatitis B more than 2,000 ten thousand people at present.There are 23.7 ten thousand people to die from the relevant disease of hepatitis B every year, wherein have 15.6 ten thousand people to die from liver cancer.So what the whole world was extremely urgent is find a kind of medicine that can reduce HBV infection rate and treatment chronic hepatitis as early as possible.
Entecavir tablet is studied by Bristol-Myers Squibb Co. of the U.S. (Bristol-Myers Squibb), exploitation, and U.S. food Drug Administration (FDA) is in official approval on March 29 in 2005 Entecavir (English trade(brand)name: Baraclude).Entecavir is white or off-white powder, easily molten in DMF, and slightly separate in 0.1mol/L hydrochloric acid and 0.1mol/L sodium hydroxide, slightly soluble in methyl alcohol, soluble,very slightly in water and ethanol, almost insoluble in acetonitrile, tool does not draw moist.Entecavir is cyclopentyl guanosine-analogue, and its structural formula is:
It is a kind of oral nucleoside medicine of selectivity Anti-HBV activity.This medicine oral absorption is rapid, and tissue distribution is extensive, and in kidney, concentration is higher, plasma protein binding ratio and internal metabolism rate all lower, about 60% ~ 80% with original shape from renal excretion, other meta-bolitess have glucuronide conjugate and two kinds of sulfates.This medicine was originally studied and was used for the treatment of herpes simplex infections, but it only has the suppression of moderate to simplexvirus.Found that this medicine had the effect of extremely strong suppression HBVDNA afterwards, and toxicity is very low, therefore becomes the emphasis in the Anti-HBV activity nucleoside medicine studied at present.The medicine Anti-HBV activity of the HepG2 cell of HBV DNA transfection finds in testing in vitro, and it acts on the strongest one in existing Anti-HBV activity nucleoside analog.It to hepatitis B virus (HBV) polymerase mechanism of action is: by competing with the natural substrate triphosphoric acid deoxyguanosine of HBV polymerase, Entecavir triphosphate can suppress all three kinds of activity of virus polymerase (reversed transcriptive enzyme): the startup of (1) HBV polymerase; (2) formation of pregenomic mRNA reverse transcription minus strand; (3) synthesis of HBV DNA normal chain.So it has the effect of fine effectively anti HBV infecting.
Entecavir water-soluble poor, prior art has open entecavir tablets or entecavir capsule preparation.Chinese patent application CN201310383392.X discloses a kind of entecavir capsule, Contents Fill is in capsule shell, described content is obtained pastille fine powder and mix lubricant, described pastille fine powder is that after Entecavir, meglumine and water-soluble filler being dissolved in the water, spraying dry forms, the weight ratio of Entecavir and meglumine is 1:15 ~ 50, by using a large amount of meglumines to improve the water-soluble of Entecavir, thus improve the uniformity coefficient of Entecavir.Chinese patent application CN201210004946.6 discloses a kind of entecavir capsule, its component comprises Entecavir, pregelatinized Starch and Microcrystalline Cellulose, containing Entecavir 0.5g, pregelatinized Starch 30 ~ 100g, Microcrystalline Cellulose 30 ~ 100g in 1000 capsules, lubricant 0 ~ 2g, adopt equivalent method of progressively increasing to mix by Entecavir and Microcrystalline Cellulose, then mix with pregelatinized Starch, incapsulate in shell, its dissolution rate is comparatively slow, thus onset is slow.A kind of Enticawer release-controllable capsule disclosed in Chinese patent application CN200710026680.4, the composition in capsule is Entecavir 0.01 ~ 5%, weighting agent 50 ~ 90%, tackiness agent 0.5 ~ 15%, glidant 0.1 ~ 5%; Film controlled release coat composition is film clothing material 1 ~ 15%, antisticking agent 0.1 ~ 5%, pore-creating agent 0.1 ~ 5%, softening agent 0.1 ~ 5%, its dissolution rate of this capsule is slower, and within 4 hours, discharge 26.38% activeconstituents, after 24 hours, the active ingredient of more than 94% all discharges.
Usually, for pharmaceutical preparation, the entecavir capsule preparation of concrete the application, wish that active ingredient is stablized, auxiliary material is more few better, and auxiliary material is the smaller the better to the side effect of human body, for the preparation that activeconstituents dosage is few, the difference of the active component content in each capsule needs to reduce as much as possible, in other words, ensure that active ingredient can evenly stripping be most important rapidly in auxiliary material, discharge medicine as far as possible at short notice, reach therapeutic plasma concentrations, simultaneously, obtain long-time therapeutic plasma concentrations stably, make the onset in a short time in vivo of this active ingredient, and keep drug effect for a long time, improve the conformability of patient.Special proposition the present invention for this reason.
Summary of the invention
An object of the present invention is to provide a kind of Entecavir crystalline compounds, the water-soluble of this Entecavir crystalline compounds is significantly improved.
Another object of the present invention is to provide entecavir capsule, entecavir capsule of the present invention excipient substance used has side effect hardly to human body, through experiment in vitro checking, can discharge at short notice and reach therapeutic plasma concentrations, and keep therapeutic plasma concentrations for a long time.
The preparation method being to provide a kind of entecavir capsule an object of the present invention.
For realizing object of the present invention, adopt following technical scheme:
A kind of Entecavir crystalline compounds, this crystalline compounds uses Cu-K α
1the X-ray powder diffraction of radionetric survey as shown in Figure 1.
Concrete, Entecavir crystal carries out Cu-K α
1in the X-ray powder diffraction (as shown in Figure 1) of radionetric survey, at 11.1 ° ± 0.1 °, 13.9 ° ± 0.1 °, 14.4 ° ± 0.1 °, 21.1 ° ± 0.1 °, 21.8 ° ± 0.1 °, 22.1 ° ± 0.1 °, 23.5 ° ± 0.1 °, 25.2 ° ± 0.1 °, 25.4 ° ± 0.1 ° diffraction angle (2 θ) indicating characteristic peak.
The preparation method of above-mentioned Entecavir crystalline compounds, comprises the steps:
(1) added by Entikawei solid in the mixed solvent of N,N-DIMETHYLACETAMIDE and methyl alcohol, temperature is under the condition of 35 ~ 40 DEG C, and Entikawei solid all dissolves;
(2) control temperature is under the condition of 35 ~ 40 DEG C, adds the aqueous solution of Virahol in the solution that step (1) obtains, and wherein, the mass percent containing Virahol in the aqueous solution of Virahol is 30% ~ 40%;
(3) after adding the aqueous solution of Virahol, be that 2.5 ~ 3.5 DEG C/10min is cooled to 0 ~-10 DEG C with speed, leave standstill 12 ~ 20 hours, crystallize out at 0 ~-10 DEG C, filter, filter cake washed with diethylether, after vacuum-drying, obtains Entecavir crystal.
It is preferred, and in step (1), the volume between N,N-DIMETHYLACETAMIDE and methyl alcohol is 2.0:(1.5-2.0); Preferred, the volume between described N,N-DIMETHYLACETAMIDE and methyl alcohol is 2.0:2.0.
Described Entecavir and the mass volume ratio of mixed solvent are (10-15) g:100ml.
A kind of Entecavir capsule, the weighting material in capsule comprises: Entecavir crystalline compounds, solubilizing agent, weighting agent, disintegrating agent, lubricant and tackiness agent.
Described Entecavir crystal uses Cu-K α
1as shown in Figure 1, the content of Entecavir is every 0.5mg to the X-ray powder diffraction of radionetric survey.
Weight ratio in capsule between each component is:
Described solubilizing agent comprises one or more mixing of sucrose monostearate, sucrose tristearate, polyethylene glycol 6000, poloxamer, Natvosol, hydroxypropylcellulose.
Described weighting agent comprises lactose, starch, Microcrystalline Cellulose, one or more mixing of dextrin, Icing Sugar, calcium sulfate, sucrose, N.F,USP MANNITOL, Microcrystalline Cellulose, glucose, pregelatinized Starch, magnesium oxide, calcium sulfate.
Described disintegrating agent comprises one or more mixing of sodium starch glycolate, low-substituted hydroxypropyl methylcellulose, starch, Microcrystalline Cellulose, croscarmellose sodium, polyvinylpolypyrrolidone, Lalgine, Citric Acid, Polysorbate 80, glycyl Starch Sodium.
Described lubricant comprises one or more mixing of silicon-dioxide, Magnesium Stearate, talcum powder, hydrogenated vegetable oil, aluminum hydroxide gel, magnesium oxide, paraffin, white oil, glycerine, glycine, glyceryl monostearate.
Described tackiness agent comprises one or more mixing of hydroxypropylcellulose, starch slurry, Xylo-Mucine, dextrin, polyvidone, ethyl cellulose, ethanol.
The preparation method of above-mentioned Entecavir capsule, comprises the steps:
(1) configure binder solution, place for subsequent use;
(2) 100 mesh sieves are for subsequent use excessively respectively to get the Entecavir crystalline compounds of recipe quantity, weighting agent, disintegrating agent, lubricant;
(3) weighting agent is mixed with the disintegrating agent of recipe quantity, make mixed accessories;
(4) by Entecavir crystalline compounds and solubilizing agent mixing, the mixed accessories then pressing equal increments method and step (3) mixes;
(5) with binder solution softwood, granulation, drying; Drying temperature controls at 50 ~ 60 DEG C;
(6) dried particle is carried out whole grain, then mix with lubricant, then filled capsules, obtain entecavir capsule.
Compared with prior art, Entecavir crystalline compounds provided by the invention increases than the water-soluble of Entecavir, and more stable.The entecavir capsule that Entecavir crystal is made has that release rate is fast, effective blood drug concentration holds time long feature.
Accompanying drawing explanation
The X-ray powder diffractogram of Fig. 1 Entecavir crystalline compounds of the present invention
The entecavir capsule of Fig. 2 embodiment of the present invention 4 contrasts with listing sample stripping curve schemes
Embodiment
Below that entecavir compound prepared and entecavir capsule of the present invention and preparation method are described in further detail:
Embodiment 1
Added by 10g Entikawei solid in the mixed solvent 100ml of N,N-DIMETHYLACETAMIDE and methyl alcohol, the volume between N,N-DIMETHYLACETAMIDE and methyl alcohol is 2.0:1.5, and temperature is under the condition of 40 DEG C, and Entikawei solid all dissolves; Control temperature, under the condition of 35 ~ 40 DEG C, adds the aqueous solution of Virahol in the solution obtained, and wherein, the mass percent containing Virahol in the aqueous solution of Virahol is 35%; After adding the aqueous solution of Virahol, be that 3.5 DEG C/10min is cooled to-5 DEG C with speed, leave standstill 13 hours, crystallize out at-5 DEG C, filter, filter cake washed with diethylether, after vacuum-drying, obtains Entecavir crystal.Cu-K α is carried out to products obtained therefrom Entecavir crystal
1in the X-ray powder diffraction (as shown in Figure 1) of radionetric survey, at 11.1 °, 13.9 °, 14.4 °, 21.1 °, 21.8 °, 22.1.9 °, 23.5 °, 25.2 °, 25.4 °, ° diffraction angle (2 θ ± 0.1) display diffraction peak.
Embodiment 2
Added by 15g Entikawei solid in the mixed solvent 100ml of N,N-DIMETHYLACETAMIDE and methyl alcohol, the volume between N,N-DIMETHYLACETAMIDE and methyl alcohol is 2.0:2.0, and temperature is under the condition of 35 DEG C, and Entikawei solid all dissolves; Control temperature, under the condition of 35 ~ 40 DEG C, adds the aqueous solution of Virahol in the solution obtained, and wherein, the mass percent containing Virahol ethanol in the aqueous solution of Virahol is 30%; After adding the aqueous solution of Virahol, be that 2.5 DEG C/10min is cooled to-10 DEG C with speed, leave standstill 18 hours, crystallize out at-10 DEG C, filter, filter cake washed with diethylether, after vacuum-drying, obtains Entecavir crystal.Show through the analysis of powder X-ray RD detector, conform to the result shown in accompanying drawing 1.
Embodiment 3
Added by 12 Entikawei solids in the mixed solvent 100ml of N,N-DIMETHYLACETAMIDE and methyl alcohol, the volume between N,N-DIMETHYLACETAMIDE and methyl alcohol is 2.0:2.0, and temperature is under the condition of 40 DEG C, and Entikawei solid all dissolves; Control temperature, under the condition of 35-40 DEG C, adds the aqueous solution of Virahol in the solution obtained, and wherein, the mass percent containing Virahol ethanol in the aqueous solution of Virahol is 40%; After adding the aqueous solution of Virahol, be that 3.0 DEG C/10min is cooled to 0 DEG C with speed, leave standstill 20 hours, crystallize out at 0 DEG C, filter, filter cake washed with diethylether, after vacuum-drying, obtains Entecavir crystal.Show through the analysis of powder X-ray RD detector, conform to the result shown in accompanying drawing 1.
Embodiment 4
Entecavir capsule prescription
The preparation method of Entecavir capsule, comprises the steps:
(1) take a certain amount of hypromellose, make the hypromellose cellulose solution of 2% with water, place for subsequent use;
(2) the Entecavir crystal raw material of recipe quantity and each auxiliary material are crossed 100 mesh sieves respectively for subsequent use;
(3) take lactose, starch, carboxymethylstach sodium by recipe quantity, lactose, starch, carboxymethylstach sodium are mixed, makes mixed accessories;
(4) the Entecavir crystalline compounds of recipe quantity and sucrose tristearate are mixed, the mixed accessories then pressing equal increments method and step (3) mixes;
(5) with 2% hypromellose aqueous solution softwood, 20 mesh sieves granulate, 50 ~ 60 DEG C of dryings;
(6) dried particle is carried out whole grain, more fully mix with the silicon-dioxide of recipe quantity, then filled capsules, obtains entecavir capsule.
Embodiment 5
Entecavir capsule prescription
The preparation method of Entecavir capsule, comprises the steps:
(1) take a certain amount of polyvidone, make the polyvidone ethanolic soln of 2% with ethanol, place for subsequent use;
(2) Entecavir crystal raw material and each auxiliary material are crossed 100 mesh sieves respectively for subsequent use;
(3) take N.F,USP MANNITOL, starch, low-substituted hydroxypropyl cellulose by recipe quantity, N.F,USP MANNITOL, starch, low-substituted hydroxypropyl cellulose are mixed, makes mixed accessories;
(4) the Entecavir crystalline compounds of recipe quantity and sucrose monostearate are mixed, then press equal increments method and the mixed accessories described in step (3) mixes;
(5) with 2% polyvidone ethanolic soln softwood, 20 mesh sieves granulate, 50 ~ 60 DEG C of dryings;
(6) dried particle is carried out whole grain, more fully mix with the Magnesium Stearate of recipe quantity, then filled capsules, obtains entecavir capsule.
Embodiment 6
Entecavir capsule prescription
The preparation method of Entecavir capsule, comprises the steps:
(1) take a certain amount of hypromellose, make the hypromellose cellulose solution of 2% with water, place for subsequent use;
(2) Entecavir crystal raw material and each auxiliary material are crossed 100 mesh sieves respectively for subsequent use;
(3) take N.F,USP MANNITOL, Microcrystalline Cellulose, carboxymethylstach sodium by recipe quantity, N.F,USP MANNITOL, Microcrystalline Cellulose, carboxymethylstach sodium are mixed, makes mixed accessories;
(4) the Entecavir crystalline compounds of recipe quantity and polyethylene glycol 6000 are mixed, then press equal increments method and step (3) described mixed accessories mixes;
(5) with 2% hypromellose aqueous solution softwood, 20 mesh sieves granulate, 50 ~ 60 DEG C of dryings;
(6) dried particle is carried out whole grain, more fully mix with the silicon-dioxide of recipe quantity, then filled capsules, obtains entecavir capsule.
Embodiment 7
Entecavir capsule prescription
The preparation method of Entecavir capsule, comprises the steps:
(1) take a certain amount of starch, make the starch slurry of 8% with water, place for subsequent use;
(2) Entecavir crystal raw material and each auxiliary material are crossed 100 mesh sieves respectively for subsequent use;
(3) take lactose, N.F,USP MANNITOL, polyvinylpolypyrrolidone by recipe quantity, lactose, N.F,USP MANNITOL, polyvinylpolypyrrolidone are mixed, makes mixed accessories;
(4) the Entecavir crystalline compounds of recipe quantity and sucrose tristearate are mixed, then press equal increments method and the mixed accessories described in step (3) mixes;
(5) with 8% starch slurry softwood, 20 mesh sieves granulate, 50 ~ 60 DEG C of dryings;
(6) dried particle is carried out whole grain, more fully mix with the talcum powder of recipe quantity, then filled capsules, obtains entecavir capsule.
Embodiment 8
Entecavir capsule prescription;
The preparation method of Entecavir capsule, comprises the steps:
(1) take a certain amount of Xylo-Mucine, make the sodium carboxymethyl cellulose solution of 1% with water, place for subsequent use;
(2) Entecavir crystal raw material and each auxiliary material are crossed 100 mesh sieves respectively for subsequent use;
(3) take N.F,USP MANNITOL, dextrin, low-substituted hydroxypropyl cellulose by recipe quantity, N.F,USP MANNITOL, dextrin, low-substituted hydroxypropyl cellulose are mixed, makes mixed accessories;
(4) the Entecavir crystalline compounds of recipe quantity and sucrose tristearate are mixed, then press equal increments method and the mixed accessories described in step (3) mixes;
(5) with 1% sodium carboxymethyl cellulose solution softwood, 20 mesh sieves granulate, 50 ~ 60 DEG C of dryings;
(6) dried particle is carried out whole grain, more fully mix with the silicon-dioxide of recipe quantity, then filled capsules, obtains entecavir capsule.
Embodiment 9
Entecavir capsule prescription;
The preparation method of Entecavir capsule, comprises the steps:
(1) take a certain amount of hypromellose, make 2% hypromellose cellulose solution with water, place for subsequent use;
(2) Entecavir crystal raw material and each auxiliary material are crossed 100 mesh sieves respectively for subsequent use;
(3) take lactose, Microcrystalline Cellulose, pregelatinized Starch by recipe quantity, lactose, Microcrystalline Cellulose, pregelatinized Starch are mixed, makes mixed accessories;
(4) the Entecavir crystalline compounds of recipe quantity and sucrose tristearate are mixed, then press equal increments method and the mixed accessories described in step (3) mixes;
(5) with 2% hypromellose aqueous solution softwood, 20 mesh sieves granulate, 50 ~ 60 DEG C of dryings;
(6) dried particle is carried out whole grain, more fully mix with the silicon-dioxide of recipe quantity, then filled capsules, obtains entecavir capsule.
Embodiment 10
Entecavir capsule prescription;
The preparation method of Entecavir capsule, comprises the steps:
(1) ethanol of measured amounts, makes the ethanolic soln of 70% with water, place for subsequent use;
(2) Entecavir crystal raw material and each auxiliary material are crossed 100 mesh sieves respectively for subsequent use;
(3) take N.F,USP MANNITOL, dextrin, Lalgine by recipe quantity, N.F,USP MANNITOL, dextrin, Lalgine are mixed, makes mixed accessories;
(4) the Entecavir crystalline compounds of recipe quantity and sucrose tristearate are mixed, then press equal increments method and the mixed accessories described in step (3) mixes;
(5) with 70% ethanolic soln softwood, granulation, 50 ~ 60 DEG C of dryings;
(6) dried particle is carried out whole grain, more fully mix with the Magnesium Stearate of recipe quantity, then filled capsules, obtains entecavir capsule.
Experimental example 1
This experimental example carries out accelerated stability test to the entecavir capsule of embodiment 4, the results are shown in Table 1:
Packaging: polyvinyl chloride solid medicinal stiff sheet, drug packaging aluminium foil, investigates condition: temperature 40 ± 2 DEG C of RH75% ± 5%
Table 1 accelerated stability test
Conclusion: to the samples of three batches after simulation commercially available back through accelerated test 6 months, every inspection target and detect results contrast in 0 month, is showed no considerable change.
Experimental example 2
This experimental example carries out in vivo test to the entecavir capsule of embodiment 4.Concrete grammar is, study subject is 28 healthy male volunteers, and the age, body weight was in (65 ± 3.0) kilogram, and height is at (1.72 ± 0.25) rice in (25 ± 1.5) year.Tested front all volunteers all check UP, and all every all normal, not used to the prejudicial medicine of internal organs within half a year, in experimenter before administration 1 month and whole off-test do not take other any medicines.Before taking medicine 24h and duration of test prohibit drink tea, quit smoking, wine, and the beverage containing caffeine and ethanol.According to random dual crossing test design, 28 healthy premenopausal volunteers are divided into two groups, fasting 12 hours, before taking medicine morning, adopt blank blood 5ml.
28 experimenters are divided into A, B bis-groups at random, often organize 14 people, the entecavir capsule and commercially available entecavir capsule of taking the embodiment of the present invention 4 is intersected respectively two cycles, the entecavir capsule of the oral embodiment of the present invention 4 of empty stomach and each 0.5mg of commercially available entecavir capsule, take medicine and can drink water in right amount for latter 2 hours, unified feed low fat light diet after 4 hours.10min, 20min, 30min, 45min, 1h, 1.5h, 2h, 3h after taking medicine, 5,8h, 12,24,48,72h gather venous blood 5ml at experimenter's upper arm respectively, get blood plasma after centrifugal, to be measured-80 DEG C of preservations.HPLC-MS/MS is adopted to measure Entecavir concentration in blood plasma.In the period 1, the entecavir capsule of the oral embodiment of the present invention 4 of A group experimenter, B group takes commercially available entecavir capsule; Be second cycle after one week, two groups exchange another kind of Entecavir formulation respectively, same method blood sample collection.By detecting the comparison of two kinds of preparation Plasma Concentration kinetic parameters, evaluate the bioequivalence of two kinds of preparations.
Adopt non-chamber dependent form parameter evaluation method, calculate pharmacokinetic parameters with DAS2.0 pharmacokinetics routine processes plasma drug concentration data, Cmax, Tmax are practical measurement numerical value.The main pharmacokinetic parameters of two kinds of preparations is in table 2:
Main pharmacokinetic parameters after the oral entecavir capsule of table 2
As can be seen from Table 2, entecavir capsule of the present invention is absorbing soon in vivo, and keeps therapeutic plasma concentrations for a long time.
Experimental example 3
This experimental example carries out dissolved corrosion simultaneous test to the entecavir capsule of embodiment 4 and the Entecavir tablet sample that goes on the market.
Get this product each 6 and listing control sample Entecavir tablet 6, respectively according to dissolution method (China's coastal port two annex Ⅹ C second methods), with 0.05mol/L potassium dihydrogen phosphate (PH6.8) 1000ml for dissolution medium, rotating speed is per minute 50 turns, operate in accordance with the law, draw solution appropriate (simultaneously adding the dissolution medium of equivalent uniform temp) the 15th, 30,45,60 minute time, filters, gets subsequent filtrate as need testing solution respectively; Separately get Entecavir reference substance appropriate, accurately weighed, add 0.05mol/L potassium dihydrogen phosphate and dissolve and dilute the solution made about containing 0.5 μ g in every 1ml, product solution in contrast.Get above-mentioned need testing solution and each 100 μ l of reference substance solution, injection liquid chromatography, record color atlas, goes out stripping quantity by external standard method with calculated by peak area, draws stripping curve and sees Fig. 2.Test-results is in table 3, table 4.
Table 3 entecavir capsule stripping curve test-results
Table 4 goes on the market sample Entecavir tablet stripping curve test-results
Experimental result shows: the entecavir capsule of embodiment 4 is fast compared with the dissolution rate of Entecavir tablet listing sample.
Claims (7)
1. an Entecavir crystalline compounds, this crystalline compounds uses Cu-K α
1the X-ray powder diffraction of radionetric survey as shown in Figure 1.
2. a preparation method for Entecavir crystalline compounds, comprises the steps:
(1) added by Entikawei solid in the mixed solvent of N,N-DIMETHYLACETAMIDE and methyl alcohol, temperature is under the condition of 35 ~ 40 DEG C, and Entikawei solid all dissolves;
(2) control temperature is under the condition of 35-40 DEG C, adds the aqueous solution of Virahol in the solution that step (1) obtains, and wherein, the mass percent containing Virahol in the aqueous solution of Virahol is 30% ~ 40%;
(3) after adding the aqueous solution of Virahol, be that 2.5 ~ 3.5 DEG C/10min is cooled to 0 ~-10 DEG C with speed, leave standstill 12 ~ 20 hours, crystallize out at 0 ~-10 DEG C, filter, filter cake washed with diethylether, after vacuum-drying, obtains Entecavir crystal,
Wherein, in step (1), the volume between N,N-DIMETHYLACETAMIDE and methyl alcohol is 2.0: (1.5 ~ 2.0); Preferred, the volume between described N,N-DIMETHYLACETAMIDE and methyl alcohol is 2.0: 2.0.
3. an Entecavir capsule, is characterized in that, main ingredient Entecavir is crystal, and described Entecavir crystal uses Cu-K α
1as shown in Figure 1, the content of Entecavir is every 0.5mg to the X-ray powder diffraction of radionetric survey.
4. Entecavir capsule according to claim 3, is characterized in that, the weighting material in capsule comprises Entecavir crystalline compounds, solubilizing agent, weighting agent, disintegrating agent, lubricant, tackiness agent.
5. Entecavir capsule according to claim 4, is characterized in that, the weight ratio in capsule between each component is:
6. the Entecavir capsule according to claim 4 or 5, it is characterized in that, solubilizing agent comprises one or more mixing of sucrose monostearate, sucrose tristearate, polyethylene glycol 6000, poloxamer, Natvosol, hydroxypropylcellulose;
Described weighting agent comprises lactose, starch, Microcrystalline Cellulose, one or more mixing of dextrin, Icing Sugar, calcium sulfate, sucrose, N.F,USP MANNITOL, Microcrystalline Cellulose, glucose, pregelatinized Starch, magnesium oxide, calcium sulfate;
Described disintegrating agent comprises one or more mixing of sodium starch glycolate, low-substituted hydroxypropyl methylcellulose, starch, Microcrystalline Cellulose, croscarmellose sodium, polyvinylpolypyrrolidone, Lalgine, Citric Acid, Polysorbate 80, glycyl Starch Sodium;
Described lubricant comprises one or more mixing of silicon-dioxide, Magnesium Stearate, talcum powder, hydrogenated vegetable oil, aluminum hydroxide gel, magnesium oxide, paraffin, white oil, glycerine, glycine, glyceryl monostearate;
Described tackiness agent comprises one or more mixing of hydroxypropylcellulose, starch slurry, Xylo-Mucine, dextrin, polyvidone, ethyl cellulose, ethanol.
7. the preparation method of the Entecavir capsule according to any one of claim 4 ~ 6, comprises the steps:
(1) take binder solution, place for subsequent use;
(2) 100 mesh sieves are for subsequent use excessively respectively to get the Entecavir crystalline compounds of recipe quantity, weighting agent, disintegrating agent, lubricant;
(3) weighting agent is mixed with the disintegrating agent of recipe quantity, make mixed accessories;
(4) by Entecavir crystalline compounds and solubilizing agent mixing, the mixed accessories then pressing equal increments method and step (3) mixes;
(5) with binder solution softwood, granulation, drying; Drying temperature controls at 50 ~ 60 DEG C;
(6) dried particle is carried out whole grain, then mix with lubricant, then filled capsules, obtain entecavir capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510372885.2A CN105001223B (en) | 2015-06-30 | 2015-06-30 | A kind of Entecavir crystalline compounds and capsule preparations thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510372885.2A CN105001223B (en) | 2015-06-30 | 2015-06-30 | A kind of Entecavir crystalline compounds and capsule preparations thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105001223A true CN105001223A (en) | 2015-10-28 |
| CN105001223B CN105001223B (en) | 2016-08-17 |
Family
ID=54374126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510372885.2A Expired - Fee Related CN105001223B (en) | 2015-06-30 | 2015-06-30 | A kind of Entecavir crystalline compounds and capsule preparations thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105001223B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112028889A (en) * | 2019-06-03 | 2020-12-04 | 鲁南制药集团股份有限公司 | Novel crystal form of deoxyguanosine analogue |
| CN112028890A (en) * | 2019-06-03 | 2020-12-04 | 鲁南制药集团股份有限公司 | Deoxyguanosine analogue crystal form |
| WO2024066765A1 (en) * | 2022-09-30 | 2024-04-04 | 广州帝奇医药技术有限公司 | Antiviral pharmaceutical composition, preparation process therefor, and use thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101693713A (en) * | 2009-10-28 | 2010-04-14 | 福建广生堂药业有限公司 | New crystal system of entecavir, preparation process and medicament application thereof |
| WO2011046303A2 (en) * | 2009-10-12 | 2011-04-21 | Hanmi Holdings Co., Ltd. | Novel method for preparing entecavir and intermediate used therein |
| CN102417506A (en) * | 2010-09-27 | 2012-04-18 | 杭州赛利药物研究所有限公司 | Preparation method of antiviral drug Entecavir |
| CN103304566A (en) * | 2013-07-09 | 2013-09-18 | 北京凯因科技股份有限公司 | Novel crystalline entecavir |
| CN103435614A (en) * | 2013-08-23 | 2013-12-11 | 四川海思科制药有限公司 | Entecavir compound |
-
2015
- 2015-06-30 CN CN201510372885.2A patent/CN105001223B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011046303A2 (en) * | 2009-10-12 | 2011-04-21 | Hanmi Holdings Co., Ltd. | Novel method for preparing entecavir and intermediate used therein |
| CN101693713A (en) * | 2009-10-28 | 2010-04-14 | 福建广生堂药业有限公司 | New crystal system of entecavir, preparation process and medicament application thereof |
| CN102417506A (en) * | 2010-09-27 | 2012-04-18 | 杭州赛利药物研究所有限公司 | Preparation method of antiviral drug Entecavir |
| CN103304566A (en) * | 2013-07-09 | 2013-09-18 | 北京凯因科技股份有限公司 | Novel crystalline entecavir |
| CN103435614A (en) * | 2013-08-23 | 2013-12-11 | 四川海思科制药有限公司 | Entecavir compound |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112028889A (en) * | 2019-06-03 | 2020-12-04 | 鲁南制药集团股份有限公司 | Novel crystal form of deoxyguanosine analogue |
| CN112028890A (en) * | 2019-06-03 | 2020-12-04 | 鲁南制药集团股份有限公司 | Deoxyguanosine analogue crystal form |
| WO2024066765A1 (en) * | 2022-09-30 | 2024-04-04 | 广州帝奇医药技术有限公司 | Antiviral pharmaceutical composition, preparation process therefor, and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105001223B (en) | 2016-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10624938B2 (en) | Total flavone extract of flower of abelmoschus manihot L. medic and preparation method thereof | |
| WO2009026790A1 (en) | Crystal entecavir fomulation and the preparation method thereof | |
| CN104688700A (en) | Readily soluble tenofovir disoproxil fumarate tablets and preparation method thereof | |
| CN111450072B (en) | Ticagrelor controlled release tablet and preparation method thereof | |
| CN105001223A (en) | Entecavir crystalline compound and capsule preparation thereof | |
| CN115518066A (en) | Pharmaceutical composition for treating anticoagulation and application | |
| CN104000789A (en) | Adefovir dipivoxil dispersible tablet and preparation method thereof | |
| CN104815025A (en) | Preparation process and quality control method of cassia twig poria cocos preparation | |
| US20170368087A1 (en) | Pharmaceutical composition comprising topiramate | |
| CN100542528C (en) | Bicyclol micronization and controlled release formulations for oral administration | |
| CN101658520A (en) | Medicinal composition for treating hyperuricemia | |
| CN101224205B (en) | Composition of atorvastatin and levorotatory amlodipine and preparing method thereof | |
| CN116262116A (en) | Solid preparation containing clopidogrel oxide and preparation method thereof | |
| CN106943356B (en) | A kind of famciclovir sustained-release granule and preparation method thereof | |
| CN102327272A (en) | Fully-novel oral solid pharmaceutical composition and preparation method thereof | |
| CN101953773B (en) | Lamivudine liposome solid preparation | |
| CN101690724A (en) | Piperazine ferulate enteric preparation and preparation method thereof | |
| CN106902097B (en) | A pharmaceutical composition for improving bioavailability of medicine | |
| CN111150713B (en) | Indapamide capsule and preparation method thereof | |
| CN100434091C (en) | Fenugreek seed extract and its preparing process and application | |
| CN103550182B (en) | Enteric-coated sustained release composition | |
| WO2020088364A1 (en) | Anti-viral infection pharmaceutical composition and preparation method therefor | |
| CN102018700B (en) | Pharmaceutical preparation containing silymarin and preparation thereof | |
| CN104434850B (en) | A kind of oral solid drug composition containing Aldoforwe ester | |
| CN104224739A (en) | Oral solid composition with entecavir serving as main ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180620 Address after: 410329 Liuyang, Hunan economic and Technological Development Zone, north of Liu Chong Road, west of healthy South Road. Patentee after: Hunan Sanqing Pharmaceutical Co., Ltd. Address before: 410331 Liuyang biological medicine garden in Changsha, Hunan Co-patentee before: Changsha Boya Medicine Technology Development Co., Ltd. Patentee before: Hunan Sanqing Pharmaceutical Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160817 Termination date: 20210630 |